Cargando…

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver

Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. In this review, we discuss the pivotal trials that led to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, So Yeon, Halmos, Balazs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399613/
https://www.ncbi.nlm.nih.gov/pubmed/32774467
http://dx.doi.org/10.2217/lmt-2020-0003